This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 12496 results found since Jan 2013.

The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
CONCLUSIONS: Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.CLINICAL TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03033732).PMID:37697811 | DOI:10.1177/07067437231194385
Source: Canadian Journal of Psychiatry - September 12, 2023 Category: Psychiatry Authors: Anees Bahji Gabriel Bastien Paxton Bach JinCheol Choi Bernard Le Foll Ron Lim Didier Jutras-Aswad M Eugenia Socias Source Type: research

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional)
Funding Opportunity RFA-AA-23-006 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) seeks to support studies that will inform safe and effective medication-assisted, psychosocial, and complementary interventions for people with co-occurring Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). Alcohol increases lethal opioid overdose risk. As a result, treatment providers may under-prescribe or be reluctant to provide opioid agonist therapies (OATs) such as methadone and buprenorphine to people with OUD who also have AUD or misuse alcohol. There is also scant research on non-pharma...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2023 Category: Research Source Type: funding

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01 Clinical Trial Optional)
Funding Opportunity RFA-AA-23-005 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) seeks to support studies that will inform safe and effective medication-assisted, psychosocial, and complementary interventions for people with co-occurring Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD). Alcohol increases lethal opioid overdose risk. As a result, treatment providers may under-prescribe or be reluctant to provide opioid agonist therapies (OATs) such as methadone and buprenorphine to people with OUD who also have AUD or misuse alcohol. There is also scant research on non-pharma...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2023 Category: Research Source Type: funding

The efficacy of buprenorphine on moderate traumatic brain injury in the rat model
CONCLUSION: These results suggest that buprenorphine causes fewer changes in behavioral functions in rats' models of mTBI and, because of their positive effect changes on inflammation biomarkers, biochemical behavioral tests, and CT scan images, could be ideal analgesic agents for pre-clinical responses after TBI.PMID:37695813 | DOI:10.1080/01616412.2023.2257447
Source: Neurological Research - September 11, 2023 Category: Neurology Authors: Hamid Reza Rasouli Mehdi Mohammadian Salim Samira Talebi Mohammad Eslamian Fathollah Ahmadpour Source Type: research

Gabapentin Use With Buprenorphine Initiation for Opioid Use Disorder
This case-control study with crossover analysis assesses the differences between patients receiving and not receiving gabapentin alongside buprenorphine in the treatment of opioid use disorder and the drug-related poisoning risk associated with gabapentin.
Source: JAMA Psychiatry - September 6, 2023 Category: Psychiatry Source Type: research

Bicycle Health, Albertsons partner to boost access to opioid use disorder injections
The telehealth company ' s providers can prescribe buprenorphine injections that patients can receive at Albertsons  pharmacies, including Safeway and Acme.
Source: mobihealthnews - September 5, 2023 Category: Information Technology Source Type: news

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Conditions:   Opioid-Related Disorders;   Substance-Related Disorders;   Narcotic-Related Disorders Interventions:   Drug: Injectable extended-release buprenorphine;   Drug: Sublingual buprenorphine-naloxone Sponsors:   Yih-Ing Hser;   National Institute on Drug Abuse (NIDA);   National Institutes of Health (NIH);   The Emmes Company, LLC;   University of California, Los Angeles;   RAND;   Cornell University;   Oregon Health and Science University;   University of Illinois at C hicago;   University of Washington;   West Virginia University Not yet recruiting
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials